MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of “Hold” from Brokerages

MoonLake Immunotherapeutics (NASDAQ:MLTX) has been given a consensus rating of “Hold” by the sixteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $25.7692.

Several research analysts recently weighed in on the company. UBS Group set a $24.00 price target on MoonLake Immunotherapeutics in a research report on Friday, January 9th. Zacks Research downgraded MoonLake Immunotherapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 20th. Oppenheimer restated an “outperform” rating and set a $30.00 price target on shares of MoonLake Immunotherapeutics in a report on Thursday, November 6th. Citigroup lowered MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a report on Wednesday, October 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of MoonLake Immunotherapeutics in a research report on Tuesday, February 3rd.

MoonLake Immunotherapeutics Price Performance

Shares of NASDAQ:MLTX opened at $15.77 on Monday. The company’s fifty day moving average is $14.92 and its two-hundred day moving average is $25.31. The company has a market cap of $1.01 billion, a P/E ratio of -4.75 and a beta of 1.20. MoonLake Immunotherapeutics has a 12-month low of $5.95 and a 12-month high of $62.75. The company has a quick ratio of 8.50, a current ratio of 8.50 and a debt-to-equity ratio of 0.25.

Insider Buying and Selling

In other MoonLake Immunotherapeutics news, insider Kristian Reich sold 72,908 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $14.43, for a total transaction of $1,052,062.44. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Da Silva Jorge Santos sold 70,000 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $14.49, for a total value of $1,014,300.00. Following the transaction, the chief executive officer directly owned 2,878,577 shares in the company, valued at approximately $41,710,580.73. This represents a 2.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 402,908 shares of company stock valued at $5,987,162 over the last quarter. Corporate insiders own 12.05% of the company’s stock.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

A number of institutional investors have recently modified their holdings of the company. Kestra Advisory Services LLC acquired a new position in MoonLake Immunotherapeutics in the 4th quarter valued at $26,000. FNY Investment Advisers LLC acquired a new stake in shares of MoonLake Immunotherapeutics in the third quarter valued at about $28,000. Bank of America Corp DE grew its position in shares of MoonLake Immunotherapeutics by 64.7% in the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock valued at $32,000 after purchasing an additional 1,781 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of MoonLake Immunotherapeutics by 115.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after purchasing an additional 3,166 shares during the period. Finally, Covestor Ltd acquired a new position in shares of MoonLake Immunotherapeutics during the 3rd quarter worth about $46,000. Institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.